<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_BGU_Israel_Part_improvement skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:BGU Israel/Part improvement</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV id="header_img_div" align="center" width="100%"><H1 class="firstHeading">Team:BGU Israel</H1></DIV><DIV id="content"><DIV id="bodyContent"><DIV id="header-container"><DIV id="menu"><UL><LI><A id="home" href="https://2015.igem.org/Team:BGU_Israel">Home</A></LI><LI>Project
                            </LI><LI><A id="A3" href="https://2015.igem.org/Team:BGU_Israel/Description">Description</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Design">Design</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Results">Results</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Experiments">Protocols</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Collaborations">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Achievements">Achievements</A></LI></UL><LI><A id="A2" href="https://2015.igem.org/Team:BGU_Israel/Team">Team</A></LI><LI><A id="A2" href="https://2015.igem.org/Team:BGU_Israel/Team">Team</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Attributions">Attributions</A></LI><LI> Practices
            </LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Practices">Practices and Polices</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Entrepreneurship">Entrepreneurship</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Ethics">Ethics</A></LI><LI>Parts
            		</LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Parts">Team Parts</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Basic_Part">Basic Parts</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Part_improvement">Part Improvement</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Part_Collection">Part Collection</A></LI><LI><A id="A4" href="https://2015.igem.org/Team:BGU_Israel/Notebook">Notebook</A></LI><LI><A href="https://2015.igem.org/Team:BGU_Israel/Safety">Safety</A></LI></DIV></DIV></DIV></DIV><DIV id="Div1"><DIV id="wikicontent-container"><DIV id="wikicontent"><H2>Part Improvement</H2><P dir="LTR">
    Our part (<A href="http://parts.igem.org/Part:BBa_K1699001">BBa_K1699001</A>) (human short TERT promoter) is a
    significant improvement of existing part  (<A href="http://parts.igem.org/Part:BBa_K404106">BBa_K404106</A>) (phTERT
    promoter) due to the following reasons:
</P><P dir="LTR">
    1. Our part is shorter (378 bp vs 459 bp), thus permitting more flexible design in various scenarios when construct length could be a critical issue.
</P><P dir="LTR">
    2. Our part adds extensive characterization results in human cancer cells, showing data of promoter validation, and, importantly, functional data where
    hTERT promoter was used to successfully control the expression of dCas9-VP64 in cancer-specific CRIPSR-based activation system. In the original part,
    actual experimental data is missing.
</P><P dir="LTR">
    Specifically, we show:
</P><P dir="LTR">
    1) GFP expression under short human TERT promoter exclusively in cancer cells (Figure 1).
</P><P dir="LTR">
    Fig.1. GFP expression under short human TERT promoter in human cancer cells (fibrosarcoma) and healthy fibroblasts, after calcium phosphate plasmid
    transfection (<STRONG>A</STRONG>) or AAV transduction (<STRONG>B</STRONG>). Bar: 200 micron.
</P><P dir="LTR">
    2) GFP expression under synthetic activation promoter after the successful activation of Boomerang system (consisting dCas9-VP64 - under the control of
    hTERT promoter, guide RNA (targeting the synthetic activation promoter) - under the control of human survivin promoter, and GFP under synthetic activation
    promoter) (Figure 2).
</P><P dir="LTR">
    Figure 2. GFP expression from synthetic activation promoter exclusively in cancer cells after successful activation of CRISPR-based activation core driven
    by dCas9-VP64 - under the control of hTERT promoter, and guide RNA (targeting the synthetic activation promoter) - under the control of human survivin
    promoter. Bar:100 micron.
</P><P dir="LTR">
    3. The engineered design of hTERT promoter in cancer-specific CRISPR-based gene knock-out is also shown, further expanding the usability of the part
    (Figure 3).
</P><P dir="LTR"><STRONG>A</STRONG></P><P dir="LTR"><STRONG>B</STRONG></P><P dir="LTR">
    Figure 3. <STRONG>A</STRONG>. Plasmid map of AAV vector expressing SaCas9 under the control of human short TERT promoter. <STRONG>B</STRONG>. Summary of
    two cancer-specific promoter-driven CRISPR-mediated gene knock-out.
</P></DIV></DIV></DIV></DIV><DIV id="social-footer"><DIV id="follow"><H2>Follow us:</H2></DIV><DIV id="Div3"><H2>Address:</H2><DIV align="center"><TABLE style="background-color:transparent;"><TBODY><TR><TD style="border-style: hidden;background-color:transparent;"><FONT color="white">Ben-Gurion University of the Negev 
          Ben Gurion 1, Beer Sheva 8410501, Israel
          Mail: igembgu2015@gmail.com</FONT></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>